Advanced Filters
noise
Found 645 clinical trials

A LM-302 Combined With Toripalimab Phase II Study

A Phase II, Open-Label, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of LM-302 Combined With Toripalimab in CLDN18.2 Positive Patients advanced gastro-Intestinal Cancer

18 - 80 years of age All Phase 2
D Daniel J Renouf, MD

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

This study will investigate whether or not it is feasible to closely monitor and manage glucose levels in people with pancreatic cancer. It will also investigate what impact glucose management may have on pancreatic cancer. This is a pilot study that will use continuous glucose monitors (CGM) to monitor glucose …

18 years of age All Phase N/A
E Eiji Oki

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

Phase I Part : Confirm the safety of GAIA-102 GAIA-102 as a single agent or GAIA-102 and pembrolizumab in combination for Advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part : Research the efficacy and safety …

20 years of age All Phase 1/2
S Site Public Contact

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used …

18 years of age All Phase 3
S Saleh K Saleh, MD

Laparoscopic Pancreaticoduodenectomy

Laparoscopic pancreaticoduodenectomy was first performed by Garner and Pomp in 1994. This is a technically difficult, time consuming and high rate of complication procedure. The reason is that duodenum and head of pancreas locate deeply in retroperitoneum and are surrounded by important structures such as inferior vena cava, abdominal aorta, …

18 - 75 years of age All Phase N/A
E Elena Rangelova, PhD, FACS

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in patients with borderline (BR) and locally advanced pancreatic cancer (LAPC). Patients with histologically confirmed non-metastatic BR/LAPC evaluated to potentially tolerate …

18 - 90 years of age All Phase 3
M Moh'd Khushman, M.D.

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).

18 years of age All Phase 1
W Wyanne Law, MD

A Study of Multiparametric Ultrasound Imaging Methods

The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The researchers will compare the results of mpUS imaging to standard ultrasound imaging and other standard …

18 years of age All Phase N/A
Y Ying Cheng, Bachelor

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

18 - 70 years of age All Phase 1/2
B Brandon Huffman, MD

ZN-c3 + Gemcitabine in Pancreatic Cancer

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) Gemcitabine (a nucleoside metabolic inhibitor)

18 years of age All Phase 2

Simplify language using AI